Laser Photonics Announces Promising Early Returns and Significant Growth Opportunities Following Control Micro Systems (CMS) Acquisition
Laser Photonics (NASDAQ: LASE) reports strong initial results from its recent Control Micro Systems (CMS) acquisition, completed for $1.05 million. In the first month post-acquisition, LPC collected nearly $600,000 in accounts receivable and secured approximately $600,000 in new CMS orders. CMS's current revenue backlog stands at over $3.7 million.
The acquisition strategically positions LPC in the pharmaceutical market, where CMS specializes in precision laser drilling systems for controlled-release pharmaceuticals. This market reached $49.5 billion in 2023 with projected 11% CAGR through 2030. CMS brings expertise in custom laser solutions across various industries, enhancing LPC's capability to offer tailored industrial laser systems.
Laser Photonics (NASDAQ: LASE) riporta risultati iniziali solidi dalla recente acquisizione di Control Micro Systems (CMS), conclusa per $1,05 milioni. Nel primo mese dopo l'acquisizione, LPC ha raccolto quasi $600.000 in crediti e ha assicurato circa $600.000 in nuovi ordini da CMS. L'attuale backlog di entrate di CMS supera i $3,7 milioni.
L'acquisizione posiziona strategicamente LPC nel mercato farmaceutico, dove CMS è specializzata in sistemi di perforazione laser di precisione per farmaci a rilascio controllato. Questo mercato ha raggiunto $49,5 miliardi nel 2023 con una crescita annua composta (CAGR) prevista dell'11% fino al 2030. CMS porta competenza in soluzioni laser personalizzate in vari settori, aumentando la capacità di LPC di offrire sistemi laser industriali su misura.
Laser Photonics (NASDAQ: LASE) informa sobre resultados iniciales sólidos de su reciente adquisición de Control Micro Systems (CMS), finalizada por $1,05 millones. En el primer mes posterior a la adquisición, LPC recaudó casi $600,000 en cuentas por cobrar y aseguró aproximadamente $600,000 en nuevos pedidos de CMS. El backlog de ingresos actuales de CMS supera los $3,7 millones.
La adquisición posiciona estratégicamente a LPC en el mercado farmacéutico, donde CMS se especializa en sistemas de perforación láser de precisión para productos farmacéuticos de liberación controlada. Este mercado alcanzó los $49,5 mil millones en 2023, con una tasa compuesta anual (CAGR) proyectada del 11% hasta 2030. CMS aporta experiencia en soluciones láser personalizadas en diversas industrias, mejorando la capacidad de LPC para ofrecer sistemas láser industriales a medida.
레이저 포토닉스 (NASDAQ: LASE)가 최근 컨트롤 마이크로 시스템즈 (CMS) 인수에 대한 강력한 초기 결과를 보고했습니다. 이 인수는 105만 달러에 완료되었습니다. 인수 후 첫 달에 LPC는 약 600,000달러의 외상 매출금을 회수하고 CMS에서 약 600,000달러의 신규 주문을 확보했습니다. CMS의 현재 매출 백로그는 370만 달러를 초과합니다.
이 인수는 LPC를 제약 시장에서 전략적으로 위치시킵니다. CMS는 제어 방출 의약품을 위한 정밀 레이저 드릴링 시스템을 전문으로 합니다. 이 시장은 2023년에 495억 달러에 달했고, 2030년까지 11%의 CAGR 성장률이 예상됩니다. CMS는 다양한 산업에 걸쳐 맞춤형 레이저 솔루션에 대한 전문 지식을 제공하여 LPC가 맞춤형 산업용 레이저 시스템을 제공할 수 있는 능력을 향상시킵니다.
Laser Photonics (NASDAQ: LASE) fait état de résultats initiaux solides suite à la récente acquisition de Control Micro Systems (CMS), finalisée pour 1,05 million de dollars. Au cours du premier mois suivant l'acquisition, LPC a collecté près de 600 000 dollars en créances et a sécurisé environ 600 000 dollars de nouvelles commandes CMS. Le carnet de commandes actuel de CMS dépasse 3,7 millions de dollars.
Cette acquisition positionne stratégiquement LPC sur le marché pharmaceutique, où CMS se spécialise dans des systèmes de perçage laser de précision pour les médicaments à libération contrôlée. Ce marché a atteint 49,5 milliards de dollars en 2023, avec un taux de croissance annuel composé (CAGR) projeté de 11 % jusqu'en 2030. CMS apporte une expertise en solutions laser sur mesure dans divers secteurs, améliorant ainsi la capacité de LPC à offrir des systèmes laser industriels personnalisés.
Laser Photonics (NASDAQ: LASE) berichtet von starken anfänglichen Ergebnissen aus der jüngsten Übernahme von Control Micro Systems (CMS), die für 1,05 Millionen Dollar abgeschlossen wurde. Im ersten Monat nach der Übernahme hat LPC fast 600.000 Dollar an Forderungen gesammelt und rund 600.000 Dollar an neuen CMS-Bestellungen gesichert. Der derzeitige Umsatzrückstand von CMS beläuft sich auf über 3,7 Millionen Dollar.
Die Übernahme positioniert LPC strategisch im Pharmamarkt, in dem sich CMS auf präzise Laserbohrsysteme für kontrollierte Arzneimittelabgabe spezialisiert hat. Dieser Markt erreichte 2023 49,5 Milliarden Dollar mit einer prognostizierten CAGR von 11 % bis 2030. CMS bringt Fachwissen in maßgeschneiderte Laserlösungen in verschiedenen Branchen mit und verbessert LPCs Fähigkeit, maßgeschneiderte industrielle Lasersysteme anzubieten.
- Immediate financial returns: $600,000 in accounts receivable collections and $600,000 in new orders within first month
- Substantial revenue backlog of $3.7 million from CMS
- Strategic entry into growing pharmaceutical market ($49.5B size, 11% CAGR)
- Acquisition cost relatively low ($1.05M) compared to immediate returns
- Diversification into recession-resistant markets
- Small equity component ($100,000 in LASE stock) may cause minimal dilution
Insights
Substantial Early Returns in First Month Post-Acquisition Highlight Strategic Potential of CMS Assets
CMS Revenue Backlog Has Grown to over
A Promising Start to a Strategic Acquisition
The CMS acquisition represents a strategic milestone for LPC, diversifying its business into recession-resistant markets and significantly expanding its engineering capabilities. The early results demonstrate the untapped potential of CMS’ assets.
With a customer base that includes some of the world’s largest pharmaceutical manufacturers, CMS is well-positioned to scale under Laser Photonics’ leadership. The company remains optimistic about the long-term revenue and profit contributions this acquisition will deliver.
Capitalizing on the Growing Pharmaceutical Market
CMS specializes in precision laser systems for pharmaceutical applications, notably laser drilling systems used in controlled-release pharmaceutical production. These systems enable manufacturers to create microscopic apertures in tablets, ensuring precise control over drug release rates—a critical function in modern drug delivery systems.
The broader market for controlled-release pharmaceuticals reached
Wayne Tupuola, CEO of Laser Photonics commented:
“We see a tremendous opportunity to expand CMS’ presence in the pharmaceutical market. The combination of its innovative technologies and our robust sales and marketing infrastructure provides a pathway to scale their solutions, penetrate deeper into existing pharmaceutical customer bases, and attract new clients in this high-growth sector.”
Unlocking Potential in Custom Laser Systems
Beyond pharmaceuticals, CMS brings a wealth of experience in designing and delivering custom laser solutions for diverse industrial applications. This capability allows Laser Photonics to offer tailored systems that address specific customer needs across industries, from healthcare and automotive to aerospace and energy.
By integrating CMS’ custom laser expertise into its broader portfolio, Laser Photonics aims to enhance its ability to develop innovative, customer-centric solutions across its entire product line. CMS’ bespoke engineering capabilities also align with Laser Photonics’ focus on pushing the boundaries of industrial laser applications, creating significant cross-selling and product development synergies.
Tupuola added:
“CMS’ strength in delivering precision-engineered custom solutions gives us a competitive edge in addressing unique customer challenges. We’re excited to leverage their expertise across our portfolio, enabling us to offer enhanced value to existing customers while tapping into new markets.”
About Laser Photonics Corporation
Laser Photonics is a vertically integrated manufacturer and R&D Center of Excellence for industrial laser technologies and systems. Laser Photonics seeks to disrupt the
Cautionary Note Concerning Forward-Looking Statements
This press release contains “forward-looking statements” (within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended), including statements regarding the Company’s plans, prospects, potential results and use of proceeds. These statements are based on current expectations as of the date of this press release and involve a number of risks and uncertainties, which may cause results and uses of proceeds to differ materially from those indicated by these forward-looking statements. These risks include, without limitation, those described under the caption “Risk Factors” in the Registration Statement. Any reader of this press release is cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this press release except as required by applicable laws or regulations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241217828761/en/
Investor Relations and Media Contact:
Brian Siegel, IRC®, M.B.A.
Senior Managing Director
Hayden IR
(346) 396-8696
brian@haydenir.com
Source: Laser Photonics Corporation
FAQ
What are the initial financial returns from LASE's acquisition of Control Micro Systems?
How much did LASE pay for the Control Micro Systems acquisition?
What is the current revenue backlog for Control Micro Systems (LASE subsidiary)?
What is the market size and growth rate for controlled-release pharmaceuticals where LASE now operates?